Phase IV Clinical Trial to Evaluate Safety of Eribulin in Patients With Locally Advanced or Metastatic Breast Cancer

Trial Profile

Phase IV Clinical Trial to Evaluate Safety of Eribulin in Patients With Locally Advanced or Metastatic Breast Cancer

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Oct 2016

At a glance

  • Drugs Eribulin (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Acronyms ESKIMO
  • Sponsors Eisai Korea
  • Most Recent Events

    • 28 Apr 2016 Status changed from active, no longer recruiting to completed.
    • 04 Dec 2015 Planned End Date changed from 1 Dec 2016 to 1 Jan 2016, according to ClinicalTrials.gov record.
    • 11 Aug 2015 Planned End Date changed from 1 Jul 2016 to 1 Dec 2016 according to ClinicalTrials.gov record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top